Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageBausch + Lomb is a subsidiary of Bausch Health Companies Inc. (“BHC”), with BHC directly or indirectly holding 310,449,643 Bausch + Lomb common shares, which represents approximately 88% of the issued and outstanding common shares of Bausch + Lomb, as of February 11, 2026. On August 6, 2020, BHC announced its plan to separate our eye health business into an independent publicly traded entity, separate from the remainder of BHC (the “Separation”).
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Business segments
Q4 2024 · $1.28BThe company’s own SEC segment disclosure.
- United States and Puerto Rico$657.0M51%
- Other Countries$197.0M15%
- China$96.0M8%
- France$51.0M4%
- Japan$50.0M4%
- United Kingdom$35.0M3%
- Other (8)$194.0M15%
Bausch + Lomb Corporation (BLCO) reported revenue of $1.24B in Q1 2026 (quarter ended Mar 31, 2026), up 9.4% from the same quarter a year earlier. That came with net loss of $71M. For the full year FY2025, revenue was $5.10B (+6.5% year on year) and net income −$360M. Its largest region in Q4 2024 (quarter ended Dec 31, 2024) was United Statesand Puerto Rico at $657M, 51% of the disclosed total, well ahead of Other Countries at 15%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
Ranks #13 of 19 by Smart Score